Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G.
Santini D, et al.
Curr Cancer Drug Targets. 2011 Jan;11(1):123-9. doi: 10.2174/156800911793743600.
Curr Cancer Drug Targets. 2011.
PMID: 20578980
Free article.
Review.